Organon & Co.
Organon & Co. (OGN): 43 pipeline candidates · 2 upcoming catalysts · ~13 mo cash runway · 22 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.1 months
D/E 13.39 · 0% dilution
Lead: Approved
43 candidates
2 upcoming, next in ~105d
1 buy · 0 sells (180d)
A transparent, data-derived signal for Organon & Co.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.5B
Cash
$1.1B
Quarterly Burn
$517.0M
Runway
13.1 mo
Revenue
$1.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (43 candidates)
| Drug | Phase |
|---|---|
| amikacin elution disk for autobac | Approved |
| asmanex hfa | Approved |
| Atozet 10/40 mg or 10/80 mg | Phase 4 |
| autobac mic test system | Approved |
| Aybintio (SB8) | Approved |
| Brenzys (SB4) | Approved |
| Cerazette | Approved |
| Claria System | — |
| curesis plasma separator | Approved |
| dulera | Approved |
Showing 10 of 43 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
610
Total value held
$1.29B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 31,717,028 | $190.0M |
| vanguard capital management llc | 23,474,036 | $140.6M |
| vanguard portfolio management llc | 21,846,036 | $130.9M |
| state street corp | 9,956,774 | $59.6M |
| millennium management llc | 7,081,535 | $42.4M |
| eversource wealth advisors, llc | 130,011 | $41.8M |
| kahn brothers group inc | 5,536,993 | $33.2M |
| canada pension plan investment board | 5,011,100 | $30.0M |
| geode capital management, llc | 4,759,337 | $28.5M |
| private management group inc | 4,374,108 | $26.2M |
Showing top 10 of 610 institutional holders of Organon & Co.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Organon & Co.'s pipeline?
Organon & Co. (OGN) has 43 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Organon & Co.'s lead drug candidate?
Organon & Co.'s most advanced tracked candidate is amikacin elution disk for autobac (Approved) for Microbiology.
What is Organon & Co.'s next catalyst?
Organon & Co.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects" — expected October 1, 2026.
What is Organon & Co.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Organon & Co. has approximately 13.1 months of cash runway.
What is Organon & Co.'s market capitalization?
Organon & Co.'s market capitalization is approximately $3.5B.
Get the full picture on Organon & Co.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.